Price Models for Multi-indication Drugs: A Systematic Review

Campillo-Artero, Carlos; Puig‐Junoy, Jaume; Segú-Tolsa, José Luis; Trapero-Bertran, Marta

doi:10.1007/s40258-019-00517-z

Cited by 32 publications

(34 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These include the fact that at maximum prices per indication, this favors pharmaceutical companies over health authorities [112]. This approach could potentially lead to higher prices for the patients who benefit the most, which is an issue where there are already high patient co-payments [56,113].…”

Section: Differential/tiered Pricing Including Multi-indication Pricingmentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

Introduction: There are growing concerns among European health authorities regarding increasing prices for new cancer medicines, prices not necessarily linked to health gain and the implications for the sustainability of their healthcare systems. Areas covered: Narrative discussion principally among payers and their advisers regarding potential approaches to the pricing of new cancer medicines. Expert opinion: A number of potential pricing approaches are discussed including minimum effectiveness levels for new cancer medicines, managed entry agreements, multicriteria decision analyses (MCDAs), differential/tiered pricing, fair pricing models, amortization models as well as de-linkage models. We are likely to see a growth in alternative pricing deliberations in view of ongoing challenges. These include the considerable number of new oncology medicines in development including new gene therapies, new oncology medicines being launched with uncertainty regarding their value, and continued high prices coupled with the extent of confidential discounts for reimbursement. However, balanced against the need for new cancer medicines. This will lead to greater scrutiny over the prices of patent oncology medicines as more standard medicines lose their patent, calls for greater transparency as well as new models including amortization models. We will be monitoring these developments.

show abstract

Section: Differential/tiered Pricing Including Multi-indication Pricingmentioning

confidence: 99%

Potential approaches for the pricing of cancer medicines across Europe to enhance the sustainability of healthcare systems and the implications

Godman

Hill

Simoens

et al. 2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

show abstract

“…So a form of multi-use pricing is likely to be required, allowing prices to differ for a treatment depending upon the disease area it is being used in, and/or depending on whether it is being used as monotherapy or in a particular combination [1,9,10]. Multi-use pricing has been much debated, with concerns raised (and disputed) around the impact on consumer and producer surpluses [9][10][11][12][13]. In this case we are proposing it be used specifically to enable a lower price to be paid for a backbone therapy when it is in combination use rather than in monotherapy use, enabling patient access to effective combination therapies (provided that they are costeffective with the revised backbone therapy price).…”

Section: What Can Be Done?mentioning

confidence: 99%

Not cost-effective at zero price: valuing and paying for combination therapies in cancer

Latimer

Towse

Henshall

2021

Expert Review of Pharmacoeconomics & Outcomes Research

View full text Add to dashboard Cite

“…In most OECD countries, the entire population is covered for a core set of health products and services, which generally includes medicines. There are few exceptions: 8.5% of the population was uninsured in the United States in 2018, around 7.5% in Poland, and between 5% and 6% in Chile, the Slovak Republic, Estonia, and Hungary (Berchick, Barnett and Upton, 2019 [81]; OECD, 2019 [82]). In Canada, Medicare does not include coverage for prescription medicines and the extent of public coverage is determined at provincial level.…”

Section: Cost-sharing and Medicine Prices Affect Affordabilitymentioning

confidence: 99%